Bone Biologics Corporation
Price Action
Technical Summary
CONSOLIDATINGBone Biologics Corporation is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 30), showing significant lag compared to the market leaders. Earnings contraction of 34% provides fundamental context to the price action. Investors should exercise caution due to high volatility (79% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.32 | +4.55% | ABOVE |
| 50 SMA | $1.31 | +5.08% | ABOVE |
| 100 SMA | $1.27 | +8.61% | ABOVE |
| 150 SMA | $1.41 | -2.31% | BELOW |
| 200 SMA | $1.61 | -14.27% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BBLG in an uptrend right now?
BBLG has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is BBLG overbought or oversold?
BBLG's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is BBLG outperforming the market?
BBLG has a Relative Strength (RS) Rating of 30 out of 99. BBLG is currently lagging the broader market.
Where is BBLG in its 52-week range?
BBLG is trading at $1.38, which is 33% of its 52-week high ($4.13) and 11% above its 52-week low ($1.05).
How volatile is BBLG?
BBLG has a Beta of 1.62 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.